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Neurodegenerative diseases (NDs) are characterized by selective loss of neurons 
in the central nervous system (CNS). Some general symptoms of NDs are movement 
abnormalities, emotional disturbance, and memory loss1. These symptoms impair 
the patient’s quality of life. A group of NDs, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and Amyotrophic lateral sclerosis (ALS) are the most 
common and the most costly to society2. The onset of these diseases is age-related, 
affecting mostly elderly and the incidence increases due to the global increase in 
the aging population. In 2006, worldwide 26.6 million people suffered from AD, and 
this number is predicted to increase to 106.2 million in 20503. The accumulation 
of toxic, misfolded proteins in the brain is common in all of these diseases4. Some 
NDs in this group are caused by mutations in known disease-causing genes and 
are inherited, however, most cases are sporadic. Another group of NDs, the polyQ 
diseases, such as Huntington’s disease (HD) and different types of Spinocerebellar 
ataxias (SCAs), are mostly inherited, and the onset of polyQ diseases is also 
age-dependent5. There is no cure for NDs, and the mechanisms behind the 
neurodegeneration-inducing processes need further investigation. Knowledge of 
these processes is necessary for the development of potential future therapies.
In NDs, neuronal death can occur through apoptosis or necrosis6,7. Apoptosis is 
essential for various biological processes, such as development, cell turnover, and 
immune responses8. However, in NDs, excessive apoptosis leads to undesired 
neuronal death and contributes to neurodegeneration7. A number of pathological 
features of NDs are able to trigger apoptosis, such as misfolded proteins, 
mitochondrial dysfunction9, endoplasmic reticulum (ER) stress, oxidative stress10, 
and neuroinflammation11. Apoptosis is characterized by the activity of proteases 
called caspases, which cleave proteins in the cell, resulting in fragmentation of 
the cell into apoptotic bodies. Necrosis can be induced by energy depletion, lack 
of oxygen and nutrients, and has been reported in a number of NDs associated 
with misfolded or aggregated proteins6. Elevation of intracellular calcium levels, 
as occurs in NDs, has been associated with the induction of apoptosis as well as 
necrosis6. 
The pathogenesis of NDs is multifactorial. The accumulation of misfolded proteins, 
mitochondrial dysfunction, ER stress, oxidative stress, neuroinflammation and 
energy depletion can all contribute to the pathogenesis of various NDs. The work 
described in this thesis will mainly focus on neuroinflammation and misfolded 
proteins. These two contributory factors to NDs will be discussed in more detail in 
this chapter. 
While considerable effort has been spent on developing therapies, most have failed 
in clinical trials. Therapies have focused on decreasing aggregates, for example by 




initially, but some of these failed in late stage, phase III clinical trials. The same is 
true for therapies aiming to decrease oxidative stress. Some success in AD13 but 
not in HD14, has been booked with therapies aimed at decreasing inflammation in 
the brain. Further development of therapies would benefit from further knowledge 
about signaling pathways and cells that contribute to NDs.
Pathogenesis 
Protein misfolding
The most common age-related NDs are associated with misfolded proteins which 
are able to form aggregates4. This shared feature can be contributed to an age-
related decline in proteostasis15 and explain why age is a common feature of 
these diseases. AD is characterized by the presence of two kinds of aggregates: 
extracellular plaques in which the major constituent is the misfolded amyloid β (Aβ) 
peptide, and intracellular tangles which contain tau, a microtubule-associated protein 
(reviewed in16). In PD patients, dopaminergic neurons are affected and show the 
presence of cytoplasmic inclusion bodies, which consist of misfolded α-synuclein17. 
PolyQ diseases, including HD and six types of SCAs, are characterized by the 
expansion of polyglutamine (PolyQ) repeats in specific genes. The expansion of 
the polyQ repeats results in misfolded proteins that form intracellular aggregates5. 
Accumulation of misfolded proteins in the CNS is toxic to neurons and causes 
neuronal loss. Misfolded proteins can acquire a toxic gain of function and 
accumulate in organelles, resulting in impaired cellular functions (reviewed in15). 
In some animal models of NDs or in ND patients it has been demonstrated that 
misfolded proteins accumulate in the ER (endoplasmic reticulum), an important 
organelle for the biosynthesis of proteins. The accumulation of cytosolic misfolded 
proteins in the ER can result in ER stress and the unfolded protein response18.
Misfolded or aggregated proteins that accumulate extracellularly can bind to 
specific receptors on cells and induced intracellular signaling, which can contribute 
to neuronal stress and loss. Binding of amyloid β (Aβ) peptides to the nerve growth 
factor (NGF)-receptor can induce apoptosis19,20.
Misfolded or aggregated proteins can also serve as DAMPs (Damage-Associated 
Molecular Patterns, also known as Danger-Associated Molecular Patterns). DAMPs 
are substances that are normally intracellularly localized, but are released upon 
damage of cells and constitute a variety of agents such as mitochondrial DNA, 
ATP, and misfolded proteins21. Activation of receptors for DAMPs, present on 
immune cells, results in activation of inflammation, also called ‘sterile inflammation’. 
Examples of receptors for DAMPs are the Toll-like receptors (TLRs). In the brain, cells 
that express receptors for these DAMPs are predominantly brain-resident immune 
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cells22. DAMPs released from dying neurons can result in persistent inflammation, 
which can be detrimental to neurons23.
Neurodegeneration and neuroinflammation: the role of glia 
In the CNS, neurons are surrounded by non-neuronal cells, which are called glial 
cells. In the human brain, glial cells and neurons are present in roughly a 1:1 ratio24. 
Glial cells play an important role in maintaining neuronal functions and homeostasis 
in the CNS and mediate innate immune responses in the brain as a result from either 
infection or neuronal damage25. Two types of glial cells, microglia and astrocytes, 
both cells modulate immune responses in the brain25,26. These cells are commonly 
activated in a number of age-related NDs associated with protein aggregates. 
One underlying cause of this activation may be related to age: microglia are more 
reactive to inflammatory stimuli in older individuals, resulting in an enhanced release 
of pro-inflammatory cytokines, suggesting general changes in microglia in aging 
individuals27. However, a decreased phagocytic capacity of microglia has been 
described in mouse models of AD, which was dependent on anti-inflammatory 
cytokine IL-10, suggesting changes in alterations in both pro- and anti-inflammatory 
signaling (reviewed in28). In gene expression studies in brains of elderly, expression 
of microglia-specific genes was increased, and region-specific alterations in 
astrocyte-specific genes were observed29. Indeed, glial-specific gene expression 
was found to predict age more accurately than neuron-specific genes. This finding is 
of particular interest, given that age is a major risk factor for aggregation-associated 
NDs, but also because the preclinical stage of NDs (such as AD and HD)30, occurs 
well before the onset of clinical symptoms31. Indeed, several studies have identified 
a disease- and aging-associated microglial signature32,33,34,35,36. However, the 
contribution of most of these genes to NDs still remains to be determined. Recent 
research has identified considerable heterogeneity in microglia, and identified 
subtypes of microglia that can restrict development of neurodegenerative disease, 
as shown in a mouse model for AD35. The preclinical phase in AD, but also other 
NDs is associated with activation of microglia and astrocytes37,38. However, 
activation of microglia in AD patients in the preclinical phase of disease has been 
associated with a protective role, whereas microglial activation in later stages was 
associated with a worse pathogenesis (reviewed in39). This suggests that microglia 
can have neuroprotective and neurotoxic roles, depending on the disease stage or 
the subtype of microglia.
A breakthrough that identified microglia as contributing rather than responding 
cells in NDs came from GWAS studies that have identified microglial genes that 
increase the risk for AD, such as TREM2 (triggering receptor expressed in myeloid 




brain40. Additional research placed TREM2 in a signaling network of proteins that 
are additional risk factors for AD41. Given that after the onset of clinical symptoms 
neurons are irreversibly damaged and the course of disease can be delayed but not 
stopped, earlier intervention may be beneficial. Possibly, targeting microglia and 
astrocytes will be of clinical relevance, given their activation in the presymptomatic 
phase of disease.
In NDs, there are elevated numbers of activated astrocytes and microglia, also 
termed astrogliosis or microgliosis, and they are located on sites where aggregates 
are present (reviewed in23). In AD, activated microglia42 and astrocytes43 are 
detected at surrounding sites of aggregated Aβ depositions. In PD, activated 
microglia and astrocytes are present in the most affected brain regions44. In SCA3, 
the brain regions where neurodegeneration occurs, the subthalamic nucleus 
and the substantia nigra, contain increased numbers of activated astrocytes and 
microglia45. Pro-inflammatory actions of glia include increased expression of innate 
immune-related receptors, activation of inflammatory signaling pathways, secretion 
of pro-inflammatory cytokines, and generation of free radicals, including nitric 
oxide (NO)23. Microglia express innate immune receptors which can be activated 
by pathogen-associated molecular patterns (PAMPs)46 and DAMPs47. The disease-
associated, misfolded proteins in NDs can also serve as DAMPs. For example, 
microglia can become activated by the presence of extracellular misfolded Aβ 
peptides which bind to surface receptors on microglia, and this results in the 
release of proinflammatory factors47. In addition, astrocytes, the most abundant glial 
cell type in the CNS, also participate in immune responses in the CNS. Astrocytes 
also express many immune receptors and can be activated by immune receptor 
ligands, such as the AD-associated misfolded protein, Aβ48. 
Astrocytes in healthy brains
Astrocytes are indispensable for neuronal survival (reviewed in49). Astrocytes 
contribute to neuronal homeostasis in diverse ways: they help maintain the BBB 
(blood brain barrier), clear cellular debris, but also provide nutrients and secrete 
neurotrophins. Furthermore, astrocytes are important for the development and 
function of synapses (reviewed in50). They can also induce synaptic pruning 
by releasing complement factors, resulting in the elimination of the synapse by 
microglia. In addition, they can regulate the balance between excitatory synapses 
(such as glutamatergic synapses) and inhibitory synapses (such as GABA-ergic 
synapses) via the release of factors that can specifically induce or inhibit their 
formation49. Furthermore, astrocytes can respond to neuronal activity through their 
expression of neurotransmitter receptors and transporters51. Neuronal activity 
results in the release of neurotransmitters from synapses, which can bind to 
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astrocytic receptors. Astrocytes subsequently respond by a rise in intracellular 
calcium levels, which results in the release of calcium-dependent neurotransmitters 
or neuromodulators, also called gliotransmitters. These include glutamate, GABA, 
D-serine and ATP. Gliotransmitters contribute to neuronal function and synaptic 
transmission49. Glutamate release by astrocytes leads to increased intracellular 
calcium levels in neighbouring neurons, which can modulate neuronal activity but 
can also be neurotoxic52. Thus, astrocytes can directly regulate neuronal functions 
by releasing gliotransmitters.
Astrocytes have an important role in controlling energy supply in the brain, an organ 
with a very high metabolic demand, consuming around 20% of the total energy, 
primarily in neurons53. They establish this by modulating blood flow in the brain, 
and can increase blood flow to regions with high neuronal activity53. Moreover, 
astrocytes can store energy in the form of glycogen, providing a limited energy 
reserve for neurons. 
Astrocytes connect blood vessels with neuronal axons and synapses50, thus they are 
involved in taking up energy and nutrients, such as glucose, from blood vessels for 
transport to neurons. For instance, glucose can be taken up from blood vessels by 
astrocytes and subsequently the glucose can be transformed into glycogen, which 
is an important energy source in the CNS. In the adult brain, glycogen is mostly 
present in astrocytes, and the concentration of the glycogen varies depending on 
the brain regions. Several studies found that glycogen levels are high in the grey 
matter (reviewed in54) which is consistent with the fact that synapses, which require 
a high energy demand, are enriched in the grey matter55. 
Astrocytes are activated in responses to brain injuries due to ischemia, hypoglycemia 
or trauma. Compared to resting astrocytes, activated astrocytes are hypertrophic. 
After neuronal injury, they proliferate and form a glial scar, this structure isolates the 
damaged tissue56 and aids axonal regeneration57. There is evidence that activated 
astrocytes play a protective role after an induced injury. In a mouse model, it was 
demonstrated that astrocytic scars aid axonal regeneration after spinal cord injury, 
which was prevented by ablating astrocytic scars57. Another study performed in 
mice demonstrated that drug-induced ablation of activated astrocytes after spinal 
cord injury resulted in demyelination and loss of neurons58. However, activation of 
astrocytes can also be detrimental, as a result of the release of cytotoxic molecules 
and chronic inflammation in the brain59. For instance, activated astrocytes produce 
a number of pro-inflammatory cytokines, such as TNF-α, TNF-β, IL-1 and IL-660. The 
functions of astrocytes that are important for neuronal health may be altered once 
they become activated under disease-induced circumstances, which can in turn 





In most NDs, aggregates and activated astrocytes are detected before clinical 
symptoms appear (reviewed in61). A marker that is commonly used to mark 
activated astrocytes and to discriminate them from other glia is by levels of GFAP 
(glial fibrillary acidic protein). While astrogliosis is correlated with the severity of for 
example AD62 and HD63, the contribution of astrocytes to pathogenesis is unclear.
A number of molecular triggers can activate astrocytes in NDs. For example, an 
increase in the amount of pro-inflammatory cytokines released from neurons and 
other glial cells contribute to the activation of astrocytes. Prolonged activation of 
astrocytes leads to increased pro-inflammatory factors produced by astrocytes, 
which may cause more neuronal damage. A recent report identified a subtype of 
astrocytes (A1 astrocytes) that are neurotoxic and which are induced by activated 
microglia64. These astrocytes have elevated levels of components of the complement 
cascade, which are harmful to synapses. A1 astrocytes are abundant in a number 
of NDs, including AD, PD and HD, suggesting that these astrocytes contribute to 
neuronal death in NDs.
As mentioned, astrocytes play a role in regulating levels of neurotransmitters. This 
regulation may be altered in activated astrocytes in NDs. For instance, extracellular 
glutamate can contribute to excitotoxicity in neurons65. It has been shown that 
activated astrocytes have impaired capacity to take up the extracellular glutamate, 
because the expression of glutamate transporters is lower or dysfunctional in these 
activated astrocytes. This has been shown in HD66 and AD67. Therefore, impaired 
capacity of astrocytes to take up extracellular glutamate may contribute to neuronal 
loss. 
A number of studies suggest that the function of astrocytes in energy metabolism 
changes in NDs. For instance, after exposing to Aβ peptide, the glucose metabolism 
in cultured astrocytes changed, including increased glucose utilization and glycogen 
storage68. Moreover, there are studies which show that changes in cerebral glucose 
metabolism are one of the early features in AD patients69. However, the contribution 
of activated astrocytes to the metabolic changes in NDs is not clear yet70 
Altogether, in NDs, progressive loss of neurons in the CNS can be induced by 
neuronal accumulation of misfolded toxic proteins, which contributes in a cell-
autonomous manner to neurotoxicity. In addition, both astrocytes and microglia 
can cell non-autonomously contribute to neuronal homeostasis. In NDs, alterations 
in microglia and astrocytes importantly contribute as well. While some of the 
mechanisms by which these cells can have either beneficial or detrimental effects 
have been identified, the effect of altered expression in microglia and astrocyte-
specific genes still awaits further analysis. 
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Regulation of inflammation- a central role for NF-κB
Transcription factors that are commonly activated in inflammatory and stress 
responses are members of the NF-κB (Nuclear Factor Kappa Beta) transcription 
factor family. Deregulation of NF-κB has been linked to a variety of disorders, 
including cancer, immune disorders and NF-κB is chronically activated in a variety 
of inflammatory diseases (reviewed in71). Furthermore, constitutive activity of NF-κB 
in aging has been reported (reviewed in72). NF-κB is rapidly activated in response 
to a number of responses, including cytokines, reactive oxygen species, calcium, 
neurotransmitters, DAMPs, as well as components from bacterial cell walls, such as 
LPS. In mammals, 5 members of this family have been identified. The modulation 
and specificity of their activation occur via distinct signaling pathways. However, 
some crosstalk between these pathways exists as well, since these transcription 
factors can form both homodimers and heterodimers (reviewed in73). In the brain, 
NF-κB can be involved in inflammation74, but also in synaptogenesis, as well as 
neuronal growth and survival (reviewed in75). NF-κB can be activated in neurons, 
microglia and astrocytes, although the stimuli involved in activation or repression of 
NF-κB varies depending on cell type (reviewed in76). 
Activation of NF-κB commonly occurs in NDs, and has been associated with their 
pathogenesis. In a mouse model for ALS, NF-κB activation in microglia induces 
gliosis, resulting in death of motor neurons77. Elevated activation of NF-κB was found 
in astrocytes in HD patients as well as in HD mouse models, and this activation 
contributes to HD pathogenesis78. In brains of postmortem AD patients, elevation 
of levels of NF-κB or NF-κB activation was found (reviewed in79). NF-κB activation 
as well as dysregulation of calcium signaling has been shown in astrocytes of AD 
patients and in cultured astrocytes exposed to amyloid beta peptides, resulting 
in the production of pro-inflammatory cytokines (reviewed in80). In other models 
for neuroinflammation, astrocyte-specific inactivation of NF-κB improved clinical 
outcome (reviewed in81).
Therapies in NDs that targeted inflammation by using NSAIDs (non-specific anti-
inflammatory drugs) have shown some promise in AD82. An inhibitor that targets 
NF-κB was also used as a therapy, which was successful in a model for MS 
(multiple sclerosis), where NF-κB activity was specifically inhibited in astrocytes 
but not in microglia, concomitant with attenuation of demyelination83. However, 
this inhibitor had no effect on HD (reviewed in14). One possible explanation for 
this may be that multiple NF-κB isoforms are targeted, and not just the isoform(s) 
that promote the inflammatory responses. Some progress has made in generating 
inhibitors that specifically target a specific NF-κB isoform that is associated with 
inflammation and neurodegeneration84. Thus, more specificity in targeting NF-κB 




the transcriptional targets that modulate neurotoxicity in neurodegeneration may 
provide future options for therapeutically targeting NF-κB in neuroinflammation.
Aim of this thesis: analysis of astrocytes in neurodegeneration
It is no longer a matter of debate that neuroinflammation can have detrimental 
contributions in age-related NDs. Further knowledge on contributing pathways, 
communication between neurons, microglia and astrocytes may ultimately result 
in the identification of suitable therapeutic targets. In this thesis, we focus on 
contributions of astrocytes to neurodegeneration. The analysis is complex, given 
that contributions of astrocytes to neurodegeneration can be beneficial as well as 
detrimental. 
In this thesis, we examine how astrocytic responses to neurons that express an 
aggregation-prone, neurodegeneration-associated protein can influence the extent 
of neurodegeneration (Figure 1). These so-called cell non-autonomous responses 
of astrocytes have not been studied extensively because of the complexity of 
simultaneous manipulation of gene expression in both neurons (to express an 
aggregation-prone protein) and astrocytes (to manipulate expression of genes that 
may contribute to neurodegeneration). Examining astrocytes in an in vivo model is 
key, given that they are altered outside their physiological context (reviewed in11). We 
have used the fruit fly Drosophila melanogaster as a model organism, given (1) the 
large conservation of genes between fly and human (2) the presence of astrocytes 
that are similar in function (reviewed in85) and (3) the ease of genetic manipulation 
and availability of genetic tools. Flies have successfully been employed as model 
organism for human NDs86 and have been crucial in genetic screens to identify 
novel players in a multitude of biological processes. In addition, analysis of a large 
number of genes is facilitated by the short generation time (10 days) and lifespan 
(60-80 days), the low costs and availability of fly lines that allow genome-wide 
manipulation of gene expression of conserved genes. 
In this thesis, we have analyzed the cell non-autonomous contributions of astrocytes 
in a model for neurodegeneration. In this model, the human SCA3-associated 
protein containing an expanded polyQ repeat was expressed in Drosophila eyes 
or in neurons. Eye-specific expression of this protein results in eye degeneration 
and neuronal degeneration when expressed in neurons87. Employment of this SCA3 
model has resulted in the identification of genes that contribute to pathogenesis in a 
cell-autonomous manner88. In this thesis, we have set up a Drosophila SCA3 model 
that allows genetic manipulation of genes in astrocytes. We carried out a candidate 



















Figure 1. A model for the aim of this thesis. Damage in neurons, as occurs in neurodegeneration, result in the 
activation of microglia and astrocytes. Here, we examine the signaling in astrocytes in response to expression 
of ND-associated misfolded proteins in neurons. The signals that contribute to the activation of astrocytes are 
still elusive. Some findings from the literature, show that misfolded disease-related proteins and cytokines can 
activate astrocytes. Other signals, such as neurotransmitters and other DAMPs have not been identified yet. 
Importantly, the effect on neurodegeneration of signals that are subsequently released from astrocytes will 





Outline of this thesis
Chapter 2 A Drosophila screen elucidates roles for signaling molecules in cell 
non-autonomous effects of astrocytes on neurodegenerative disease 
In this chapter, we describe the generation of a Drosophila SCA3 eye model that 
allows analysis of the influence of genes in astrocytes on a degenerative eye 
phenotype. We describe the results of a candidate RNAi screen in astrocytes, to see 
whether genes expressed in astrocytes can influence the degenerative SCA3 eye 
phenotype. We identified astrocytic genes that are enhancers as well as suppressors 
of SCA3, demonstrating cell non-autonomous roles of astrocytes in degeneration. 
We further speculate on the relevance of these genes in neurodegeneration.
Chapter 3 Inhibition of NF-κB in astrocytes delays neurodegeneration in a cell 
non-autonomous manner
In this chapter, we further analyze the NF-κB transcription factor Relish, a gene 
analogous to human NF-κB1, which was identified as an enhancer of SCA3 in 
the candidate RNAi screen described in chapter 2. Downregulation of Relish 
expression, but also of transcriptional targets of Relish in astrocytes decreased 
SCA3-induced eye degeneration. Relish, but not the other Drosophila NF-κB 
transcription factors Dif and Dorsal influenced degeneration, demonstrating 
specificity of NF-κB transcription factors. We further analyzed the effect of Relish on 
lifespan in neurons expressing a SCA3-associated polyQ protein and we examined 
the effect on lifespan in neurons expressing amyloid beta peptides, associated with 
Alzheimer’s disease. Inhibition of Relish in astrocytes extended lifespan in both 
models, suggesting a general cell non-autonomous role of this NF-κB pathway in 
astrocytes in NDs. 
Chapter 4 Specific calcineurin isoforms are involved in Drosophila Toll immune 
signalling
In chapter 2, we identified Relish, but not NF-κB transcription factors Dif and Dorsal 
as an enhancer of neurodegeneration. In this chapter, we analyzed specificity 
of upstream signaling pathways that result in activation of Relish or Dif/Dorsal, 
respectively. The canonical pathways that activate Relish and Dif/Dorsal are the 
IMD and Toll pathway, respectively. However, additional pathways can modulate 
their activity. Here we analyze the different isoforms of calcium-dependent serine/
threonine phosphatase, calcineurin, on activity of Relish and Dif/Dorsal. Analysis 
of this calcium-dependent phosphatase is also of interest in NDs, where elevation 
of intracellular calcium levels commonly occurs. In Drosophila there are three 
calcineurin catalytic subunits, and all of them in astrocytes contributed to a cell non-
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autonomous effects on SCA3 (Chapter 2). In this chapter, we demonstrate specificity 
of calcineurin isoforms in Relish and Dif/Dorsal activation. We investigated this in 
cell culture, but also in NF-κB-mediated immune activation in vivo. 
Modulation of activity of calcineurin may be of relevance in regulating the activity of 
specific NF-κB transcription factors in NDs. 
Chapter 5 General Discussion
The results presented in this thesis demonstrate that astrocytes contribute to 
neurodegeneration in a cell non-autonomous manner. We mainly focused on 
putative interactions between astrocytes and neurons. However, other types of non-
neuronal cells, such as microglia, may also contribute to neurodegeneration and 
influence activity of astrocytes. In this chapter, the involvement of microglia in ND, 
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